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Abstract
AIM
To improve anti-inflammatory activity while reducing 
drug doses, we developed a nanoformulation carrying 
dexamethasone and butyrate.
METHODS
Dexamethasone cholesteryl butyrate-solid lipid nano-
particles (DxCb-SLN) were obtained with the warm 
microemulsion method. The anti-inflammatory activity of 
this novel nanoformulation has been investigated in vitro  
(cell adhesion to human vascular endothelial cells and 
pro-inflammatory cytokine release by lipopolysaccharide-
induced polymorphonuclear cells) and in vivo  (disease 
activity index and cytokine plasma concentrations in a 
dextran sulfate sodium-induced mouse colitis) models. 
Each drug was also administered separately to compare its 
effects with those induced by their co-administration in SLN 
at the same concentrations. 
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RESULTS
DxCb-SLN at the lowest concentration tested (Dx 2.5 
nmol/L and Cb 0.1 µmol/L) were able to exert a more 
than additive effect compared to the sum of the individual 
effects of each drug, inducing a significant in vitro  
inhibition of cell adhesion and a significant decrease of 
pro-inflammatory cytokine (IL-1β and TNF-α) in both 
in vitro  and in vivo  models. Notably, only the DxCb 
nanoformulation administration was able to achieve a 
significant cytokine decrease compared to the cytokine 
plasma concentration of the untreated mice with dextran 
sulfate sodium-induced colitis. Specifically, DxCb-SLN 
induced a IL-1β plasma concentration of 61.77% ± 3.19%, 
whereas Dx or Cb used separately induced a concentration 
of 90.0% ± 2.8% and 91.40% ± 7.5%, respectively; 
DxCb-SLN induced a TNF-α plasma concentration of 30.8% 
± 8.9%, whereas Dx or Cb used separately induced ones 
of 99.5% ± 4.9% and 71.1% ± 10.9%, respectively.
CONCLUSION
Our results indicate that the co-administration of dexa-
methasone and butyrate by nanoparticles may be beneficial 
for inflammatory bowel disease treatment.
Key words: Inflammatory bowel disease; Drug delivery 
systems; Nanoparticles; Dexamethasone; Butyrate
© The Author(s) 2017. Published by Baishideng Publishing 
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Core tip: The oral treatment with dexamethasone and 
butyrate co-loaded into nanoparticles was effective in 
achieving strong anti-inflammatory effects at doses 
significantly lower than those required for each single 
drug. This nanoformulation may open a new window on 
the treatment of chronic inflammatory conditions such 
as inflammatory bowel disease, where dose- and time-
dependent side effects can limit the drug’s therapeutic 
usefulness. Notably, dexamethasone cholesteryl butyrate-
solid lipid nanoparticles significantly relieved and repaired 
colon inflammation in a colitis mouse model thanks to the 
nanoformulation, which displayed an additive synergism 
among the corticosteroid, dexamethasone, and the short-
chain fatty acid, butyrate.
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INTRODUCTION
Inflammation is a physiological process that involves 
different cells, such as leukocytes and endothelial 
cells that establish adhesive interactions in order 
to transverse the vascular wall and migrate to the 
damaged tissue. Inflammatory bowel diseases 
(IBDs), including ulcerative colitis and Crohn’s di­
sease, are comprised of chronic and deregulated 
inflammation of the intestinal mucosa characterized by 
active inflammation, tissue destruction and repeated 
attempts at tissue repair that lead to a waxing­waning 
course. This persistent inflammation is triggered by 
neutrophil and macrophage infiltration, with activated 
macrophages producing a potent mixture of broadly 
active inflammatory cytokines, including interleukin (IL)-
1β and tumor necrosis factor (TNF)­α[1,2]. In response 
to such pro­inflammatory cytokines, endothelial cells 
undergo inflammatory activation, resulting in an 
increased surface expression of cell adhesion molecules 
(CAMs), such as ICAM­1, VCAM­1 and E­selectin[3]. 
These endothelial CAMs play a fundamental role 
in leukocyte recruitment from the blood for tissue 
infiltration. Chronic induction of these CAMs leads to 
abnormal leukocyte recruitment, like that observed 
in chronic inflammatory diseases characterized by 
profound tissue remodeling and loss of function[4]. 
Recently, the traditional therapeutic approach 
of IBD, with the introduction of biologic agents, has 
moved away from non­specific immunomodulators, 
including corticosteroids, thiopurines, and methotrexate 
toward a pathway-based anti-inflammatory approach. 
Even though the introduction of TNF inhibitors such as 
infliximab, as well as anti-integrins, has initiated a new 
therapeutic era, these biologics are clinically effective 
only in a subgroup of IBD patients[5,6]. Therefore, IBD 
treatment is still a difficult challenge, and efforts to 
facilitate effective drug treatment are still necessary. 
Corticosteroids exert their anti­inflammatory and 
immunosuppressive effects by reducing the expression 
of cytokines and adhesion molecules, inhibiting 
leukocyte traffic and access to the inflammation site. 
In particular, dexamethasone (Dx) has been used for 
decades in the treatment of IBD flares, even if a such 
life­long treatment might produce several adverse 
reactions that are mostly time­ and dose­dependent, 
limiting its clinical usefulness[1,7,8]. Hence, attempts to 
maintain the IBD therapeutic effects of corticosteroids 
while minimizing their systemic side effects might 
provide a major therapeutic improvement.
With regard to corticosteroids and pharmaceutical 
technology, to date only the novel oral formulation of 
budesonide using multi­matrix (MMX) drug delivery 
technology has been introduced as a treatment option 
for patients with ulcerative colitis, allowing a wider 
colonic targeting with low systemic bioavailability. The 
MMX strategy is an extension of the pH­responsive 
polymer technique that allows the sustained release of 
a drug enclosed within a gastro­resistant, pH­dependent 
coating[9]. However, it seems likely that all such systems 
relying on pH­responsive polymers will not be truly 
colon site-specific[10]. 
Recent advances in nanotechnology have enabled 
the development of new corticosteroid formu­
lations with a nanometric approach to ameliorate 
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pharmacological properties, resulting in increased 
efficacy and reduction of side effects[11]. Different 
from the MMX strategy, the nanoparticle drug delivery 
strategy relies on the nanosize as the cardinal property 
for interaction with biological systems. Indeed, the 
nanosize determines the ability to penetrate cell 
membranes, thus facilitating the passage across 
biological barriers, interaction with the immune 
system, uptake, absorption and distribution[12]. For 
instance, the size of orally assumed nanoparticles 
may somehow determine their fate, addressing the 
kind of cell with which to interact (i.e., epithelial or 
phagocytic cells), or the depth level in the intestinal 
mucosa. Moreover, nanoparticles can directly enter 
into phagocytic cells populating the inflamed tissue, 
thus providing a wider distribution and an additional 
mechanism for drug targeting[13].
Furthermore, the potential inhibitory effect of 
nanoparticle formulations of Dx on cyclooxygenase­2 
(COX­2) expression is interesting. Although the 
physiological activity of COX-2 may provide a benefit 
to the organism, its aberrant expression has been 
implicated in the pathogenesis of many diseases, 
such as chronic inflammation and carcinogenesis[14]. 
Moreover, the effective inhibitory activity displayed by 
nanoparticle formulations of Dx on CAM expression 
by “inflamed” endothelial cells may be beneficial in 
blunting detrimental inflammatory reactions[15,16]. 
In particular, the incorporation of Dx into solid lipid 
nanoparticles (SLN) showed a significant improvement 
of its anti­inflammatory activity in a human IBD 
whole-blood model. SLN loaded with Dx exerted 
earlier anti­inflammatory effects and at lower doses 
than free Dx, highlighting how this nanoparticle for­
mulation may be of therapeutic interest[17]. It is well­
known that nanoparticles are efficiently taken up 
by immunocompetent cells, so that nanoparticulate 
drug carriers may be useful in targeting the inflamed 
regions. Indeed, in the presence of IBD there is a 
strong cellular immunoresponse from the inflamed 
regions, and the nanoparticle passive targeting may 
allow for the accumulation of the drug loaded into the 
nanoparticulate carrier in the inflamed area[11]. 
Furthermore, our group investigated whether the 
association between Dx and another anti­inflamma­
tory agent such as butyrate might be of therapeutic 
interest in IBD. Butyrate is a short­chain fatty acid 
(SCFA) normally released by intestinal epithelial cells, 
which exhibit several physiological and immunological 
functions[18]. Like other SCFA, such as acetate and 
propionate, butyrate has regulatory effects on the 
proliferation, differentiation, gene expression and 
immune regulation of colon epithelial and immune 
cells. In particular, in experimental models, butyrate 
has been demonstrated to stimulate mucus production 
by colon epithelial cells, to inhibit colon inflammation 
and oxidative stress, and to improve the colon defense 
barriers, inhibiting colon carcinogenesis as well[19­21]. 
Butyrate has emerged as a modulator of adaptive 
responses, owing to its multiple biofunctions, i.e., 
restoring transforming growth factor­β (TGF­β) and 
IL-10 production in the colonic mucosa, inducing T 
cell apoptosis and dampening interferon­γ (IFN­γ) 
secretion[22,23]. Clinical trials have shown the 
effectiveness of butyrate monotherapy and/or in 
combination with conventional treatment in patients 
with diversion colitis, acute radiation proctitis, as 
well as ulcerative colitis[24­27]. In this regard, in 
the 1990s non­controlled pilot clinical trials using 
oral administration or enemas of butyrate yielded 
promising results in ulcerative colitis patients[28]. 
However, extended confirmatory studies have not yet 
been performed. On the other hand, in a randomized, 
double­blind, placebo­controlled study on ulcerative 
colitis patients, the combined treatment of oral sodium 
butyrate tablets in combination with mesalazine 
significantly decreased the disease activity index 
score and improved disease outcomes with respect to 
mesalazine alone[26].
Therefore, owing to partial patient compliance 
or restricted indications, these treatments were not 
established as a standard of care. Recent studies have 
renewed the expectations in regard to strategies related 
to intestinal SCFA. The administration of probiotic 
bacteria with the capacity to produce butyrate has 
been shown to improve the symptoms in IBD models 
in vivo[29]. Moreover, the treatment with butyrate has 
been shown to increase apoptosis and differentiation, 
and to inhibit proliferation in colon, breast, gastric, 
lung, brain and pancreas cancer cells[30,31]. Butyrate 
is characterized by a short half-life, due to its rapid 
metabolism and excretion through the liver. Therefore, 
continuous administration of the drug is required in 
order to maintain therapeutic concentrations[32]. In 
addition, the use of butyrate in therapy is limited by 
its dose­dependent side effects, such as anemia, 
headache, nausea, diarrhea and abdominal cramps. 
In order to overcome these limitations, SLN have 
been proposed for improving butyrate therapy, in 
that they constitute a drug delivery system able to 
ensure high drug loading, enhanced drug pharmacoki­
netic profile, good biocompatibility and scale­up 
feasibility[33­35]. The use of SLN has been under 
investigation in various preclinical and clinical trials, 
especially in cancer therapy, and their employment 
has been approved for clinical use in some cases[36]. 
Cholesteryl butyrate (Cb) as a butyrate SLN formulation 
has been evaluated in several in vitro and in vivo 
studies as an anticancer agent[37­41] and only in in vitro 
studies as anti-inflammatory agent[17,42]. 
Thus, our group sought to develop a new SLN 
formulation carrying dexamethasone and cholesteryl 
butyrate (DxCb) and investigated the efficacy of this 
strategy in strengthening the effect of each single 
drug in the treatment of inflammation. Specifically, 
investigations of this new anti-inflammatory SLN 
formulation were carried out in the following IBD 
models: (1) in vitro, evaluating the effects on cell 
adhesion to human vascular endothelial cells and on 
pro-inflammatory cytokine release by lipopolysaccharide 
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by tangential flow filtration (cut­off 30­100 kDa) to 
remove components and drug not incorporated into 
SLN, and the final product can then be filtered at 0.2 
µm for sterility or can be subjected to freeze drying. 
The Cb was prepared from cholesteryl butyrate 
(Asia Talent Chemical, Shenzen China), Epikuron 200 
(Cargill, Milano, Italy) and sodium glycocholate (PCA, 
Basaluzzo, Italy). In this formulation, cholesteryl 
butyrate lipid matrix acts as a prodrug of butyrate. 
For preparation of the DxCb-SLN, Dx 21-acetate 
(hereafter referred to as Dx; Sigma­Aldrich, Milano, 
Italy) was previously added and dissolved into melted 
cholesteryl butyrate matrix before adding other 
excipients as by the preparation protocol of Cb. The 
full compositions of warm microemulsions used to 
prepare Cb and DxCb-SLN are reported in Table 1. 
The temperature of these warm microemulsions was 
85 ℃ for both. After clear microemulsions had been 
obtained, they were dispersed in cold water (2 ℃) 
under stirring, at a 1:5 volume ratio. The dispersions 
obtained were then washed by tangential flow 
filtration (Vivaflow50 membrane with cut­off of 100 
kDa; Sartorius Stedim Biotech GmbH, Goettingen, 
Germany) by adding and removing the same volume 
of water 4 times (4 washings); the final concentrations 
of the main components are reported in Table 2. In 
both formulations, 2­phenylethanol was added to aid 
in microemulsion formation. In particular, it works 
mainly to reduce viscosity and further helps in the 
formation of an interface between the oil phase and 
the lipid phase. Due to the multiple washings applied 
to purify the final products - four washings in this case 
­ the concentration of 2­phenylethanol was strongly 
reduced in the final dispersion, where it finally acted as 
a preservative. Dx (water:ethanol 9:1, 1 mmol/L) was 
also prepared as a free drug reference. 
Physical characterization was performed by 
dynamic light scattering (DLS) (Malvern Zetasizer 
- Nano ZS; Malvern Instruments, Malvern, United 
Kingdom). The data are reported in Table 3. Finally, 
electron microscopy analysis by ZEISS Supra 40 Field 
Emission Scanning Electron Microscopy confirmed the 
regular shape and nanosize of the particles (Figure 1) 
(courtesy of Prof. Pirri, Laboratory FESEM Microscopy, 
DISAT, Politecnico of Torino).
Cell lines
Leukemic human T cells (Jurkat, clone E6-1) were 
obtained from American Type Culture Collection (ATCC) 
(Manassas, VA, United States), and were cultured in 
RPMI 1640 medium supplemented with 10% fetal 
calf serum (FCS) (v/v), 2 mmol/L L­glutamine and 
antibiotics (100 U/mL streptomycin and 200 U/mL 
penicillin) (Sigma­Aldrich). 
Human vascular endothelial cells (HUVECs) were 
isolated from human umbilical veins from healthy 
parturients aged between 18­35 years undergoing a 
natural birth (informed consent was obtained from 
all donors). The umbilical cord was collected at birth 
(LPS)-induced polymorphonuclear cells; and (2) in vivo, 
evaluating the effects in dextran sulfate sodium­induced 
mouse colitis.
MATERIALS AND METHODS
Preparation and characterization of DxCb-SLN
Cb and DxCb-SLN were obtained with the warm 
microemulsion method (patent WO0030620). This 
process is based on mixing, in precise ratio, the melted 
lipid matrix loaded with hydrophobic drug with water 
phase (maintained at the same melting temperature 
as the lipid matrix) which contains surfactants, mainly 
phospholipids, and other co­surfactants, like SCFA, bile 
salts or short­chain fatty alcohols. When a clear warm 
microemulsion is obtained, it is dispersed in cold water 
(2 ℃) to generate nanoparticles by solidifying the lipid 
matrix. The SLN dispersion obtained is then washed 
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Molar composition of warm 
microemulsion
Cb, mmol/L DxCb-SLN, mmol/L
Dexamethasone 21-acetate -     8.1
Cholesteryl butyrate 273.7 273.7
Epikuron™ 200 (purified 
phosphatidylcholine 92%)
335.5 335.5
Sodium glycocholate 194.8 194.8
Cb: Cholesteryl butyrate; DxCb-SLN: Dexamethasone cholesteryl butyrate-
solid lipid nanoparticles.
Table 1  Composition of warm microemulsion for cholesteryl 
butyrate and dexamethasone cholesteryl butyrate-solid lipid 
nanoparticles formulations
Molar composition of final 
dispersion after washing
Cb, mmol/L DxCb-SLN, mmol/L
Dexamethasone 21-acetate -   1.1
Cholesteryl butyrate 36.0 38.5
Phosphatidylcholine 48.4 49.2
Sodium glycocholate 12.5 11.2
Cb: Cholesteryl butyrate; DxCb-SLN: Dexamethasone cholesteryl butyrate-
solid lipid nanoparticles.
Table 2  Concentration of main components of water 
dispersion of cholesteryl butyrate and dexamethasone 
cholesteryl butyrate-solid lipid nanoparticles formulations 
after 4 washing steps (HPLC method determination)
Physical characterization 
DLS analysis
Cb DxCb-SLN
Zave in nm 79.6 72.9
Polydispersity index     0.25     0.28
Cb: Cholesteryl butyrate; DxCb-SLN: Dexamethasone cholesteryl butyrate-
solid lipid nanoparticles.
Table 3  Average value of hydrodynamic diameter (Zave) 
and polidispersity index of cholesteryl butyrate and 
dexamethasone cholesteryl butyrate-solid lipid nanoparticlesfo
rmulations
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and stored at 4 ℃ until the isolation procedure by 
trypsin treatment (1%). HUVECs were cultured in 
M199 medium with the addition of 20% FCS (v/v) 
and 100 U/mL penicillin, 100 mg/mL streptomycin, 5 
UI/mL heparin, 12 mg/mL bovine brain extract and 
200 mmol/L glutamine (Sigma-Aldrich). HUVECs were 
grown to confluence in flasks and used between the 
second and fifth passages; HUVEC viability was not 
affected by the drug treatment. 
Peripheral blood mononuclear cells (PBMCs) were 
isolated from heparinized peripheral rat blood samples 
by density­gradient centrifugation over Ficoll­Paque 
(Pharmacia Biotech, Uppsala, Sweden) according to the 
method of Liu et al[43] (the study was approved by the 
Ethics Committee of the University of Torino). PBMCs 
were cultured in RPMI 1640 medium supplemented with 
10% FCS (v/v), 2 mmol/L L­glutamine and antibiotics 
(100 U/mL streptomycin and 200 U/mL penicillin). All 
the cell lines were cultured at 37 ℃ in a humidified 5% 
CO2­95% air incubator.
In vitro cell adhesion assay
HUVECs were grown to confluence in 24-well culture 
plates, washed and rested for 1 d in M199 medium 
plus 10% FCS (v/v). Cells were pre­activated with 
IL-1β (0.01 µmol/L) for 1 h and then exposed or not 
exposed to increasing concentrations of Dx (2.5, 25 
and 250 nmol/L), Cb (0.1, 1 and 10 µmol/L) and DxCb-
SLN (2.5 nmol/L:0.1 µmol/L, 25 nmol/L:1 µmol/L and 
250 nmol/L:10 µmol/L) for 24 h, washed with fresh 
medium twice and incubated for 1 h with Jurkat cells (1 
× 105 per well). The 1 h incubation time was chosen 
to allow full sedimentation of the adhering cells, but 
similar results were obtained with shorter incubation 
times (10 and 20 min). After incubation, non­adherent 
cells were removed by being washed three times with 
M199 medium. The center of each well was analyzed 
by fluorescence imaging[42]. Adherent cells were 
counted by the ImagePro Plus Software for micro­
imaging (version 5.0; Media Cybernetics, Bethesda, 
MD, United States). Single experimental points were 
assayed in triplicate, and the standard error of three 
replicates was always below 10%. Data are shown as 
the percentage of inhibition of treated cells versus the 
control adhesion measured on untreated cells (control 
adhesion was 65 ± 5 cells per microscope field; n = 5). 
In vitro PBMC assay
PBMC viability was assayed by trypan blue dye 
exclusion, and 5 × 105/mL viable cells were cultured in 
24­well culture plates with culture medium containing 
1 µg/mL LPS (Sigma-Aldrich) for 24 h. PBMCs were 
then incubated with increasing concentration of Dx 
(2.5, 25 and 250 nmol/L), Cb (0.1, 1 and 10 µmol/L) 
and DxCb-SLN (2.5 nmol/L:0.1 µmol/L, 25 nmol/L:1 
µmol/L and 250 nmol/L:10 µmol/L) for 24 h. In order 
to exclude the possibility that the drugs might affect 
cell viability, 24 h after drug incubation a trypan blue 
dye exclusion assay was performed for each condition. 
The IL-1β and TNF­α protein concentrations in 
culture supernatants of PBMCs were determined at 24 
h incubation by specific enzyme-linked immunosorbent 
assay (ELISA) (eBioscience, Thermo Fisher Scientific, 
Milano, Italy) according to the manufacturer’s 
instructions. Data are shown as the percentage of the 
cytokine secretion of LPS-treated PBMCs after each 
drug treatment versus the cytokine secretion of control 
cells, i.e., LPS-stimulated PBMCs.
Animals
Male, 8 wk-old BALB/c mice, with an average weight 
of 18 g, were obtained from Charles River (Milano, 
Italy). The mice were housed in a specific pathogen-
free environment, and a 12 h light/dark cycle was 
maintained. The mice had access to water and rodent 
laboratory chow ad libitum; the weights of the mice as 
well as diarrhea were recorded daily. The procedures 
for the care and handling of the animals used in the 
study were approved by the local “Animal Use and Care 
Committee” (protocol number 12201), and they were in 
accordance with the European Directive 2010/63/EU on 
the protection of animals used for scientific purposes.
In vivo model of colitis 
Colitis was induced in mice by adding 4% (w/v) 
dextran sulfate sodium salt (DSS, molecular weight 
40000) (Sigma­Aldrich) to the drinking water and 
allowing ad libitum access, starting from day 0 for 5 
d. Groups of mice (at least 5 mice per group) were 
then orally treated (by gavage) daily with Dx (0.0001 
mg/g bw), Cb (0.004 mg/g bw) or DxCb-SLN (0.0001 
mg/g bw:0.004 mg/g bw) starting from day 6 for 3 
d. Moreover, in a group in which colitis was induced, 
as a sham treatment mice were administered orally 
with sterile phosphate­buffered saline solution (150 
µL/mouse per day) starting from day 6 for 3 d (DSS 
group), whereas in another group colitis was not 
induced (control group). All groups were sacrificed on 
day 10. There were at least 5 mice per group, and two 
separate experiments were carried out. There was no 
significant difference in the water consumption and food 
intake of each group during all experimental periods. 
Assessment of in vivo inflammation
The mice were weighed and inspected for diarrhea 
and rectal bleeding every day. The disease activity 
index (DAI) (i.e., the combined score of weight 
loss and bleeding) was determined according to a 
standard scoring system, as previously described by 
Rachmilewitz et al[44]. Specifically, the scores were 
defined as follows: (1) bodyweight (bw) loss (0: no 
bw loss; 1: 5%­10% bw loss; 2: 10%­15% bw loss; 
3: 15%­20% bw loss; 4: > 20% bw loss); (2) fecal 
occult blood (0: no blood; 2: positive; 4: gross blood); 
and (3) diarrhea (0: no diarrhea; 1: mild diarrhea, 2: 
severe diarrhea). All groups were sacrificed on day 10.
The IL-1β and TNF­α plasma concentrations were 
determined on day 9, i.e., 24 h after the different 
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treatments by specific sandwich enzyme immunoassay 
(eBioscience, Thermo Fisher Scientific) according 
to the manufacturer’s instructions. Data are shown 
as the percentage of the cytokine secretion of DSS­
treated mice after each drug treatment vs the cytokine 
secretion of DSS­treated mice.
Statistical analysis
Results are expressed throughout as mean ± standard 
deviation of three independent experiments for in 
vitro studies and of two independent experiments for 
in vivo studies. Statistical analyses were performed 
on GraphPad Prism 6.0 software (La Jolla, CA, United 
States). The two­way or one­way analysis of variance 
and Bonferroni’s test were used to determine statistical 
significance in the different treatment groups. The 
statistical significance threshold was set at p < 0.05.
RESULTS
Effects of DxCb-SLN on in vitro cell adhesion
First, we analyzed the effect of DxCb-SLN on the 
adhesion of Jurkat cells, a widely used continuous 
model of human T lymphocytes, to HUVECs comparing 
it with the effect of the drug separately, i.e., Dx and Cb. 
In order to reproduce an inflammatory environment, 
we pre-activated HUVECs with 0.01 µmol/L IL-1β for 1 
h. The treatment with IL-1β increased Jurkat adhesion 
by 180%, and this value was used as control. The 
concentration used for each drug had been found not 
to be toxic for HUVECs.
HUVECs were treated with increasing con-
centrations of each single drug, i.e., Dx (2.5, 25 and 
250 nmol/L) and Cb (0.1, 1 and 10 µmol/L), and of 
the DxCb nanoformulation (DxCb-SLN with a Dx:Cb 
concentration of 2.5 nmol/L:0.1 µmol/L, 25 nmol/L:1 
µmol/L and 250 nmol/L:10 µmol/L) for 24 h, washed 
and used in the adhesion assay with Jurkat cells. 
Figure 2 shows that DxCb SLN inhibited cell adhesion 
to HUVEC in a concentration-dependent manner. A 
significant 43.1% ± 7.3% inhibition of cell adhesion 
was already determined at the lowest concentration 
tested of the DxCb nanoformulation (DxCb-SLN with 
a Dx:Cb concentration of 2.5 nmol/L M:0.1 µmol/L), 
reaching an 81.8% ± 11.7% inhibition of cell adhesion 
at the highest concentration tested (DxCb-SLN with 
a Dx:Cb concentration of 250 nmol/L:10 µmol/L). 
Considering the inhibition of cell adhesion determined 
by the single drugs, Dx produced a 4.2% ± 0.8% 
inhibition at the lowest concentration tested (2.5 
nmol/L), reaching a 15.4% ± 0.9% inhibition at the 
highest concentration tested (250 nmol/L) and Cb 
determined a 14.9% ± 4.3% inhibition at the lowest 
concentration tested (0.1 µmol/L), reaching a 51.6% ± 
7.8% inhibition at the highest concentration tested (10 
µmol/L). Therefore, taking all the data together, the 
nanoformulation containing Dx 2.5 nmol/L and Cb 0.1 
µmol/L was able to exert an inhibition of cell adhesion 
in a more than additive manner with respect to the 
sum of the individual effects of each drug if they had 
been used separately (Figure 2).
Effects of DxCb-SLN on in vitro cytokine production
With respect to the effects on IL-1β production in 
PBMC culture supernatant, 24 h after the incubation a 
statistically significant (p < 0.05) higher decrease of 
IL-1β compared to the effect induced by each single 
drug was observed only with the nanoformulation 
containing the lowest concentrations tested (DxCb-SLN 
with a Dx:Cb concentration of 2.5 nmol/L:0.1 µmol/L; 
Figure 3A). Assuming as 100% the IL-1β production 
of untreated PBMCs, an IL-1β production of 74.3% 
± 8.7% was observed with the nanoformulation, in 
contrast to a 98.7% ± 9.8% and a 89.1% ± 8.2% 
production with Dx (2.5 nmol/L) and with Cb (0.1 
µmol/L), respectively. On increasing the concentrations, 
no significant differences on the IL-1β production were 
H 1 = 24.49 nm
Pa 1 = 58.20 nm
Pa R1
100 nm
Figure 1  FeSEM micrograph of dexamethasone cholesteryl butyrate-solid 
lipid nanoparticles. Electron microscopy analysis showed regular shape and 
nanosize of particles by height (H) or radius (R) measurements.
Figure 2  Effect of  dexamethasone, cholesteryl  butyrate and 
dexamethasone cholesteryl butyrate-solid lipid nanoparticles on human 
vascular endothelial cell adhesiveness to Jurkat cells. Human vascular 
endothelial cells were pre-activated with IL-1β (0.01 µmol/L) for 1 h and then 
exposed or not exposed to increasing concentrations of Dx (2.5, 25 and 250 
nmol/L), Cb (0.1, 1 and 10 µmol/L) and DxCb-SLN (2.5 nmol/L:0.1 µmol/L, 25 
nmol/L:1 µmol/L and 250 nmol/L:10 µmol/L) for 24 h and then incubated with 
Jurkat for 1 h. bP < 0.01, vs Dx; dP < 0.01, vs Cb. Dx: Dexamethasone; Cb: 
Cholesteryl butyrate; DxCb-SLN: Dexamethasone cholesteryl butyrate-solid 
lipid nanoparticles.
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observed using either the DxCb nanoformulation or 
each single drug (Figure 3A).
Regarding the effects on TNF­α production in the 
PBMC culture supernatant, 24 h after incubation a 
statistically significant (p < 0.001) higher decrease of 
TNF­α compared to the effect induced by single Dx 
was observed only with the nanoformulation at the 
lowest concentrations tested (DxCb-SLN with a Dx:
Cb concentration of 2.5 nmol/L:0.1 µmol/L; Figure 
3B). Assuming as 100% the TNF­α production of 
untreated PBMCs, a TNF­α production of 19.2% ± 2.8% 
was observed with the nanoformulation, compared 
to a 58.4% ± 5.3% and a 101.3% ± 11.3% produc­
tion with Dx (2.5 nmol/L) and with Cb (0.1 µmol/L), 
respectively. On increasing the concentrations, no 
significant differences on TNF­α production were 
observed using either the DxCb nanoformulation or Dx 
single drug (Figure 3B). Therefore, in regard to all the 
data, the nanoformulation containing Dx 2.5 nmol/L 
and Cb 0.1 µmol/L was able to exert a strong decrease 
of TNF­α production in a more than additive manner 
with respect to the sum of the individual effects of each 
drug if they had been used separately (Figure 3B).
Effects of DxCb-SLN on in vivo mice colitis 
In order to evaluate the effect of the DxCb na­
noformulation on a mouse colitis model, the mice 
were divided into groups, and each was given drugs 
separately or as DxCb-SLN at the same concentrations. 
Specifically, doses of Dx (0.0001 mg/g bw), Cb (0.004 
mg/g bw) or DxCb-SLN (0.0001 mg/g bw:0.004 mg/g 
bw) per day were administered orally from day 6 to 
day 8 after the colitis induction from day 0 to day 5. 
In addition, another group was composed of untreated 
mice (DSS group), and another of mice in which colitis 
was not induced (control group). Changes in mice bw 
were significantly different between the control group 
and the DSS group starting from day 7 and between 
groups treated with Dx or Cb and the control group 
starting from day 9 (Figure 4A). Instead, a slight but 
significant change in mice bw between DxCb-SLN 
treated­group and control group was recorded only 
at the last day of observation, i.e., day 10 (p < 0.05; 
Figure 4A). According to the DAI score determined 
for each treatment group, we observed that Dx alone 
was able to induce a significant decrease of the score 
compared to untreated mice (DSS group), with a 25% 
reduction of the disease symptoms (i.e., 6.0 vs 4.5, 
p < 0.05; Figure 4B). Notably, DxCb-SLN was able 
to induce a higher significant decrease of the disease 
score compared to untreated mice, with a 42% 
reduction of the disease symptoms (i.e., 6.0 vs 3.5, p 
< 0.01; Figure 4B).
Considering the cytokine plasma concentration on 
day 9, i.e., 24 h after drug treatment, only the DxCb 
nanoformulation administration was able to achieve a 
significant cytokine decrease compared to the cytokine 
plasma concentration of the DSS group. Assuming 
as 100% the IL-1β or TNF­α production of mice with 
DSS­induced colitis on day 9, 24 h after the 3 d of oral 
treatments, only DxCb-SLN (0.0001 mg/g bw:0.004 
mg/g bw) were able to induce a significant decrease 
(Figure 5). Specifically, DxCb-SLN induced a IL-1β 
plasma concentration of 61.77% ± 3.19%, whereas 
Dx or Cb used separately induced a concentration of 
90.0% ± 2.8% and 91.40% ± 7.5%, respectively 
(Figure 5A); DxCb-SLN induced a TNF-α plasma 
concentration of 30.8% ± 8.9%, whereas Dx or Cb 
used separately induced ones of 99.5% ± 4.9% and 
71.1% ± 10.9%, respectively (Figure 5B). Thus, DxCb­
SLN significantly ameliorated DSS-induced colitis in 
the mice compared to the treatments with each drug 
separately, given that the observed anti-inflammatory 
effect was higher than what would be expected from a 
Figure 3  In vitro effect of dexamethasone, cholesteryl butyrate and dexamethasone cholesteryl butyrate-solid lipid nanoparticles on interleukin-1β and 
tumor necrosis factor-α secretion. Cells were treated with increasing concentrations of Dx (2.5, 25 and 250 nmol/L), Cb (0.1, 1 and 10 µmol/L) and DxCb-SLN 
(2.5 nmol/L:0.1 µmol/L, 25 nmol/L:1 µmol/L and 250 nmol/L:10 µmol/L) for 24 h. IL-1β (A) and TNF-α (B) secretion in culture supernatant of PBMCs stimulated with 
lipopolysaccharide (LPS; 1 µg/mL for 24 h) were analyzed by ELISA. bP < 0.01, vs Dx; dP < 0.01, vs Cb. Dx: Dexamethasone; Cb: Cholesteryl butyrate; DxCb-SLN: 
Dexamethasone cholesteryl butyrate-solid lipid nanoparticles; IL: Interleukin; TNF: Tumor necrosis factor.
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simple additive effect (Figures 4 and 5).
DISCUSSION
In a previous work, we observed that the incorporation 
of butyrate and Dx separately into SLN was effective 
in enhancing the anti­inflammatory activity of the 
drugs on PBMCs of IBD patients[17]. In the research 
presented herein, we observed that the combination 
therapy of Dx and butyrate co­loaded into an oral 
nanoformulation, namely DxCb-SLN, was effective in 
reducing the disease activity in a mouse model of DSS­
induced colitis, as verified by its effect on macroscopic 
and biochemical parameters. 
Before moving to an in vivo IBD model, we first 
tested DxCb-SLN on in vitro inflammation models. In 
a IL-1β­stimulated leukocyte­endothelial cell adhesion 
model, where the use of the cytokine allowed us to 
reproduce the initiation phase of IBD, the combination 
treatment with DxCb-SLN was able to significantly 
inhibit cell adhesion already at the lowest concentration 
tested, showing a significant inhibition at doses 10-fold 
lower than the dose required to achieve the same 
effects with each single drug. In a LPS-stimulated 
PBMC model, DxCb-SLN demonstrated a significant 
decrease of cytokine release that was higher for 
TNF­α rather than IL-1β secretion. Once again, the 
combination treatment was more effective at doses 
10­fold lower than the dose required to achieve the 
same effects with the single drug treatment, i.e., 2.5 
nmol/L:0.1 µmol/L Cb for DxCb-SLN with respect to 25 
nmol/L for Dx and 1 µmol/L for Cb. We did not observe 
significant further decreases of both cytokine release 
at the highest concentration tested of DxCb-SLN 
because the free drugs, especially Dx, had a strong 
anti-inflammatory activity by themselves.
We then investigated this novel oral nanoformulation 
on a DSS­induced colitis in vivo model, which is one 
of the experimental models most frequently used in 
investigation of novel treatments for IBD[45]. Confirming 
the data observed in vitro, the in vivo pro-inflammatory 
cytokine release was significantly decreased by the 
DxCb-SLN oral administration, the decrease for 
TNF­α being more pronounced than IL-1β plasma 
concentration, 24 h after a daily treatment for 3 d. It 
is interesting that, on comparing the in vitro cytokine 
release at the lowest concentration of DxCb-SLN, we 
observed the same more pronounced decrease for 
A 120
100
80
60
40
20
0
In
 v
iv
o
 r
el
at
iv
e 
IL
-1
β 
se
cr
et
io
n 
at
 2
4 
h 
(%
 o
f 
co
nt
ro
l)
DSS         Dx         Cb    DxCb-SLN
b,d
120
100
80
60
40
20
0In
 v
iv
o
 r
el
at
iv
e 
TN
F-
α 
se
cr
et
io
n 
at
 
24
 h
 (
%
 o
f 
co
nt
ro
l)
DSS         Dx         Cb    DxCb-SLN
b,d
B
Figure 5  In vivo effect of dexamethasone, cholesteryl butyrate and dexamethasone cholesteryl butyrate-solid lipid nanoparticles on interleukin-1β and 
tumor necrosis factor-α secretion. Animals were treated with DSS alone (DSS), or a combination of DSS and Dx (Dx, 0.0001 mg/g bw for 3 d), DSS and Cb (Cb, 0.004 
mg/g bw for 3 d) and DSS and DxCb-SLN (DxCb-SLN, 0.0001 mg/g bw:0.004 mg/g bw for 3 d). IL-1β and TNF-α secretion in mice plasma were analyzed by ELISA 
at day 9, 24 h after drug treatment. bP < 0.01, vs Dx; dP < 0.01, Cb. Dx: Dexamethasone; Cb: Cholesteryl butyrate; DxCb-SLN: Dexamethasone cholesteryl butyrate-
solid lipid nanoparticles; DSS: Dextran sulfate sodium; IL: Interleukin; TNF: Tumor necrosis factor.
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Figure 4  In vivo effect of dexamethasone, cholesteryl butyrate and dexamethasone cholesteryl butyrate-solid lipid nanoparticles on bodyweight and 
disease activity index. Animals received no treatment (control), DSS alone (DSS), or a combination of DSS and Dx (Dx, 0.0001 mg/g bw for 3 d), DSS and Cb (Cb, 
0.004 mg/g bw for 3 d) and DSS and DxCb-SLN (DxCb-SLN, 0.0001 mg/g bw:0.004 mg/g bw for 3 d). After 7 d, DSS was replaced with a water cycle (ad libitum) 
for another 7 d. Bodyweight of the mice was recorded daily (A) and the disease activity rate at day 9 (B). bP < 0.01, vs control; cP < 0.05; dP < 0.01, vs DSS. Dx: 
Dexamethasone; Cb: Cholesteryl butyrate; DxCb-SLN: Dexamethasone cholesteryl butyrate-solid lipid nanoparticles; DSS: Dextran sulfate sodium.
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TNF­α than IL-1β secretion. 
This anti-inflammatory activity was consistent with 
the decreased DAI determined by the oral treatment 
with DxCb-SLN compared to the effects induced by the 
treatment with each drug separately. Notably, the bw 
loss induced by DSS was recovered significantly only 
after the oral treatment with DxCb-SLN. Therefore, 
thanks to this novel oral nanoformulation, the 
combination therapy of Dx and butyrate had better 
effects than any other single treatment, as specifically 
revealed by the significant decrease of plasma pro­
inflammatory cytokines, i.e., IL-1β and TNF­α, and of 
the DAI. The efficacy of DxCb-SLN demonstrated in 
these in vitro and in vivo models may be explained 
by various mechanisms, such as particular abilities of 
nanoparticulate drug delivery systems and positive 
interaction mechanisms between Dx and butyrate. 
However, further research is necessary to exa­
mine in depth the mechanism underpinning the 
enhanced anti-inflammatory effect determined by the 
simultaneous oral administration of Dx and butyrate 
as SLN formulation rather than as free drugs. For 
instance, a pharmacokinetic study comparing the 
simultaneous administration of the two drugs as free or 
loaded into the same SLN will be necessary to evaluate 
if the drug delivery system is effective in improving 
the bioavailability and inflamed tissue targeting. Also, 
molecular investigations will be necessary to evaluate 
differences in modulating inflammatory pathways by 
administering, at the same time, the two drugs as free 
or SLN formulation.
Thanks to pharmaceutical technology, we had 
the opportunity to develop an efficient drug delivery 
system able to improve the treatment of such a 
disease mediated by inflammation[11,46]. The use of 
a nanoparticulate drug carrier is useful to prevent 
early drug biological environmental degradation, to 
modulate drug pharmacokinetics, but also to enhance 
the treatment selectivity by targeting. Indeed, 
nanoparticles depending on their physico­chemical 
properties can preferentially accumulate in areas of 
intestinal inflammation when delivered orally[11,12]. 
They are particularly well­suited to the treatment 
of IBD through the local delivery of drugs to areas 
of inflammation, allowing site­specific delivery and 
minimizing side effects in other organs. 
Targeting IBD sites is a challenging task to ensure 
the release of an intact and quantitatively clear amount 
of the administered drugs. Since drugs encounter a 
harmful environment after oral administration, high 
doses and/or frequent administration are usual to 
counter the degradation by stomach acidic pH or 
small intestine digestive enzymes; on the other hand, 
the occurrence of side effects are more likely[11,47]. In 
particular, SLN have been one of most studied carriers 
worldwide for drug delivery, since this nanosystem is 
mainly composed of solid lipid core and lecithin, has 
very low toxicity profile, good affinity for biological 
membrane, ability to facilitate up­taking/overcoming, 
and capacity to improve drug pharmacokinetics[48,49].
Therefore, the therapeutic potential of this novel 
anti-inflammatory drug nanoformulation in IBD is due 
to: (1) time protection of the loaded drug, especially 
for butyrate; (2) controlled release of the loaded drug, 
allowing a prolonged drug exposure; and (3) passive 
targeting of IBD sites, as a result of the abnormal 
permeability of inflamed colonic mucosa and the 
nanoparticle preferential uptake by immunocompetent 
cells.
Moreover, because some studies have reported the 
ability of butyrate to enhance the anti­inflammatory 
activity of corticosteroids or non­steroidal drugs[50,51], 
we decided to evaluate the effect of a combination 
therapy of Dx and butyrate. It is well­known that 
butyrate may play an important role in regulating 
intestinal inflammation[52,53]. As reported by Place 
et al[22], butyrate influences NF-κB activity by preventing 
the proteasome­dependent degradation of IκBα. This 
inhibition appears to arise from butyrate’s ability to 
inhibit histone deacetylase (HDAC)[54]. Specifically, the 
selective changes in gene expression induced by HDAC 
inhibitors, such as butyrate, arise from the enhanced 
acetylation of histone proteins and gene­regulatory 
transcription factors (e.g., p53, Sp1 and Sp3)[22]. 
NF­κB is a central mediator of the immune and 
inflammatory response and, upon activation, it rapidly 
enhances the expression of pro­inflammatory genes 
such as those encoding cytokines and cell adhesion 
molecules[55]. Dx effect on cytokine modulation in IBD 
is achieved through the translocation and activation of 
the glucocorticoid­receptor complex that can both bind 
to, and inactivate, key pro-inflammatory transcription 
factors, such as NF­κB[56]. Therefore, the greater effect 
observed in both in vitro and in vivo inflammation 
models by DxCb-SLN on TNF-α rather than IL-1β 
secretion might be modulated by a gene transcriptional 
regulation of NF­κB. Thus, according to our data we 
can speculate that an additive synergistic effect on 
NF­κB modulation due to the co­administration of 
Dx and butyrate might be responsible for the higher 
anti­inflammatory effect observed compared to the 
use of each drug separately, even if further molecular 
investigations are needed to confirm this hypothesis. 
DxCb-SLN may provide a novel approach to 
treating IBD by taking advantage of a combination 
treatment achieved by co­loading Dx and butyrate 
into the same nanoparticle, which is able to exert a 
more than additive anti-inflammatory effect. Moreover, 
the pronounced anti­inflammatory activity of the 
DxCb-SLN oral treatment may be also due to passive 
targeting of the inflamed IBD sites, with the potential 
to reduce systemic side effects of each single drug in 
addition to the reduced amount of each drug required 
to achieve such an important anti-inflammatory activity.
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Background
Dexamethasone has been used for decades in the treatment of inflammatory 
bowel disease (IBD) flares, even if such a life-long treatment might produce 
several adverse reactions that are mostly time- and dose-dependent, limiting 
its clinical usefulness. Hence, attempts to maintain the IBD therapeutic effects 
of corticosteroids while minimizing their systemic side effects might provide a 
major therapeutic improvement.
Research frontiers
Nanotechnology can be used to improve the pharmacokinetic and 
pharmacodynamic properties of such a powerful drug. The authors have 
developed a nanoformulation carrying dexamethasone and the short-chain fatty 
acid, butyrate, to improve anti-inflammatory activity while reducing drug doses.
Innovations and breakthroughs
The authors developed a new solid lipid nanoparticle formulation carrying 
dexamethasone and butyrate highlighting the efficacy of this strategy in 
strengthening the effect of each single drug in the treatment of inflammation. 
Applications
This nanoformulation may open a new window on the treatment of chronic 
inflammatory conditions such as inflammatory bowel disease, where dose- and 
time-dependent side effects can limit the drug’s therapeutic usefulness. Notably, 
dexamethasone cholesteryl butyrate-solid lipid nanoparticles significantly 
relieved and repaired colon inflammation in a colitis mouse model thanks 
to the nanoformulation, which displayed an additive synergism among the 
corticosteroid, dexamethasone, and the short-chain fatty acid, butyrate.
Terminology
Solid lipid nanoparticles are mainly composed of solid lipid core and lecithin, 
have very low toxicity profile, good affinity for biological membrane, ability to 
facilitate up-taking, and capacity to improve drug pharmacokinetics.
Peer-review
This is a very interesting article discussing a novel drug delivery using 
dexamethasone cholesteryl butyrate-solid lipid nanoparticles in in vitro and in 
vivo models.
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